Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635360 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
A Phase 2 study, sponsored by Linda R Duska.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT02635360 is a Phase 2 study that has completed, run by Linda R Duska. The registered enrollment target is 94 participants.
The verdict
NCT02635360, a Phase 2 study, has completed, sponsored by Linda R Duska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION Brachytherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635360
The ClinicalTrials.gov registry entry for NCT02635360 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Linda R Duska, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02635360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02635360 about?
NCT02635360 is a clinical study titled "Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer". The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or du...
What is the current status of trial NCT02635360?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2017-02-09. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT02635360?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT02635360?
This trial is sponsored by Linda R Duska, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.